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this syndrome is increased as well. Recently, chromo-†Departments of Psychiatry, Pharmacology,
some 1q21–22 was identified as the location of a majorand Radiology
vulnerability locus for familial schizophrenia with suffi-University of North Carolina School of Medicine
cient power to permit positional cloning of the underly-
ing gene(s) (Brzustowicz et al., 2000).
Environmental factors (including exposure to infec-
tious, autoimmune, toxic, or traumatic insults and stress
Introduction during gestation or childhood) also may play a role in
Schizophrenia is a brain disorder that is expressed in the pathogenesis of schizophrenia, perhaps via subtle
the form of abnormal mental functions and disturbed alterations of neurodevelopment (Marcelis et al., 1998).
behavior. These manifestations characteristically ap- Moreoever, maturational processes including apopto-
pear in the late second and third decades of life as a sis, synaptic pruning, and myelination, occurring in the
heterogeneous constellation of three classes of clinical postnatal period through adolescence, may unmask the
features. Positive symptoms include delusions (false be- genetic vulnerability to schizophrenia (Lewis, 1997; Jar-
liefs), hallucinations (false perceptions), and thought dis- skog et al., 2000; Raedler et al., 2000). Thus, the etiology
organization. Negative symptoms refer to the loss of of schizophrenia has been conceptualized as involving
motivation and emotional vibrancy. Disturbances in ba- multiple hits (consisting of genes conferring vulnerability
sic cognitive functions, such as attention, executive and environmental insults), which are revealed in the
functions, and specific forms of memory (particularly context of developmental maturation of brain circuitry.
working memory), are also consistently observed in pa- However, unlike other genetic neurodevelopmental dis-
tients and are now thought to be central to the behavioral orders (e.g., Down’s syndrome or Fragile X syndrome),
disturbances and functional disability of schizophrenia. or severe gestational and birth traumas (e.g., fetal hyp-
In addition, many patients have concomitant mood oxia or kernicterus), there are no immediate overt mani-
symptoms including depression and anxiety that may festations of schizophrenia. Rather, most individuals ap-
contribute to the 10% lifetime incidence of suicide in pear to function normally until they enter the greatest
period of risk in late adolescence and early adulthood.schizophrenia.
The 1% lifetime incidence of schizophrenia is fairly
consistent across cultures, countries, racial groups, andEtiology
genders (Bromet and Fennig, 1999). There are, however,Vulnerability to schizophrenia is clearly related to ge-
some notable exceptions that support the involvementnetic factors (Tsuang, 2000). Family, twin, and adoption
of the hypothesized etiologic factors previously de-studies have demonstrated that the morbid risk of
scribed. Studies in both the northern and summer hemi-schizophrenia in relatives correlates with the degree of
spheres have found that persons with schizophreniashared genes. In contrast to the 1% incidence of schizo-
show a modest excess of births in the winter and springphrenia in the general population, the incidence of
months, although similar observations have been madeschizophrenia is z2% in third degree relatives (e.g., first
for depressive disorders (Torrey et al., 1997). Individualscousins) of an individual with schizophrenia, 2%–6%
with schizophrenia also tend to inhabit lower socioeco-
in second degree relatives (e.g., nieces/nephews), and
nomic strata and to be more numerous in urban and
6%–17% in first degree relatives (e.g., parents, siblings
selected immigrant populations (Mortensen et al., 1999).
or children) (Gottesman, 1991). Among twins, the inci- In addition, although equal numbers of males and fe-
dence of schizophrenia is z17% in dizygotic twins of males are affected, some data suggest that males may
affected individuals, and nearly 50% in monozygotic have more severe manifestations of the disorder, includ-
twins (Gottesman, 1991). Finally, adoption studies have ing an earlier age of onset (by 2–4 years), more marked
demonstrated that the risk of schizophrenia is related neuropathological abnormalities, poorer response to
to the presence of the disorder in biological parents but treatment, and less favorable outcome (Szymanski et
not in the adoptive parents (Gottesman and Shields, al., 1995; Hafner et al., 1998).
1982). Thus, schizophrenia appears to be a polygenic disor-
Regions on a number of chromosomes (e.g., 1, 6, 8, der and to be associated with environmental and devel-
10, 13, and 22) have been implicated as sites of potential opmental vulnerability factors. The complexity of these
vulnerability genes (Pulver, 2000). For example, 22q11– potential interactions clearly complicates research on
13 has shown suggestive findings in a number of linkage the underlying disease mechanisms. The clinical syn-
studies. Interestingly, deletions at this chromosomal re- drome recognized as schizophrenia may be a unitary
gion are associated with velo-cardio-facial syndrome (a disease process with a range of severity and clinical
congenital disorder characterized by cleft palate, car- manifestations across individuals, perhaps depending
upon the degree to which different brain regions or cir-
cuits are affected. Alternatively, the clinical heterogene-‡ To whom correspondence should be addressed (e-mail: lewisda@
msx.upmc.edu [D. A. L.], jlieberman@css.unc.edu [J. A. L.]). ity could reflect the possibility that what is recognized
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Figure 1. Clinical and Pathophysiological Course of Schizophrenia
The diagram attempts to integrate and schematically depict the clinical and pathophysiologcal course of schizophrenia in its various clinical
stages. To orient the reader starting from the top row: “Developmental Stage” describes the stage of life during which the various events and
phenomena occur; “Clinical Signs and Symptoms” refers to the mental and behavioral manifestations of the illness; “Stage of Illness” describes
all premorbid and morbid phases of the illness; “Pathologic Process” refers to the hypothesized pathogenic and pathophysiologic mechanisms
that underlie and are causal to the clinical manifestations of the disorder; “Developmental Process and Events” indicates the neurobiological
maturational processes and environmental events that may unmask or destabilize the neural circuits made vulnerable by etiologic and
pathogenic factors. The following abbreviations are DA, dopamine; NMDA, N-methyl D-aspartate; Glu, glutamate.
as schizophrenia represents a constellation of diseases Prodromal symptoms and behaviors (i.e., those that
herald the approaching onset of the illness) may includethat share some phenotypic features. Differentiating
among these possibilities will require the definitive iden- attenuated positive symptoms (e.g., illusions, ideas of
reference, magical thinking, superstitiousness), moodtification of specific causal factor(s).
symptoms (e.g., anxiety, dysphoria, irritability), cognitive
symptoms (e.g., distractibility, concentration difficul-Course of Schizophrenia
The time course of schizophrenia follows the fairly ste- ties), social withdrawal, or obsessive behaviors to name
a few (McGlashan, 1996; Yung and McGorry, 1996). Be-reotyped pattern depicted in Figure 1. High-risk and
longitudinal birth cohort studies have identified mild def- cause many of these prodromal phenomena extensively
overlap with the range of mental experiences and behav-icits in social, motor, and cognitive functions during
childhood and adolescence that may represent premor- iors of persons in the ages of risk who do not subse-
quently develop schizophrenia, they cannot be consid-bid features of the illness (Jones, 1997). For example,
subtle motor abnormalities during infancy (Walker and ered diagnostic. In the vast majority of cases, these
prodromal manifestations, and subsequently positiveLewine, 1990) and deficits in social functioning, organi-
zational ability, and intellectual functioning at ages and negative symptoms by which the diagnosis is made,
develop gradually over a period of weeks, months or16–17 have both been reported to be associated with
the later appearance of schizophrenia (Davidson et al., even years beginning some time in the mid second
through the third decade of life. The environmental1999). In addition, a number of minor physical anoma-
lies, such as variations in limb length and angle and events that typically occur during this developmental
epoch (e.g., entering college, the military or the work-finger-print patterns, are present in a subgroup of pa-
tients and can also be detected in populations with in- force, exposure to drug abuse) may act as stressors
on vulnerable neural circuits that exceed their adaptivecreased genetic risk. All of these features, however,
are mild in severity and have low predictive validity as capacity, thereby producing the behavioral symptoms
that signal the onset of the illness (Lieberman et al.,individual markers.
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1997). In contrast, schizophrenia rarely has its onset with schizophrenia, on the other (Carlsson 1988). Al-
though both postmortem and PET studies had foundbefore puberty or after age 40.
The evidence that schizophrenia is a genetically medi- increased levels of D2 receptors in the brains of schizo-
phrenia patients, antipsychotic drug treatment as theated, neurodevelopmental disorder bred the belief that
affected individuals were “doomed from the womb” and cause could not be ruled out (Wong et al., 1986; Farde
et al., 1990). More recently, direct evidence of dopaminethus had a pessimistic prognosis. In contrast, recent
studies have shown that, if treated properly early in hyperactivity has emerged from both preclinical and
clinical studies, implicating dysfunctions in presynapticthe course of their illness, most patients experience a
substantial reduction and even remission of psychotic storage, release, reuptake, and metabolic mechanisms
in dopamine meso-limbic systems (Giros et al., 1996;symptoms following an initial episode, although associ-
ated negative and cognitive symptoms can persist (Lieb- Laruelle et al., 1996; Breier et al., 1997). These studies
suggest that abnormalities in dopamine storage, vesicu-erman et al., 1993; Sheitman et al., 1997; Robinson et
al., 1999a). However, following recovery, the majority lar transport, release, or reuptake by the presynaptic
neuron may be the proximal cause of psychotic symp-of patients eventually discontinue medication and then
subsequently experience a relapse of psychotic symp- toms (Laruelle et al., 1999) and may contribute to the
risk for schizophrenia (Egan et al., 2000). It has beentoms. In the context of subsequent psychotic episodes,
they may not respond to treatment as well as in prior further hypothesized that disturbances in the presynap-
tic regulation of dopamine could lead to enduring conse-episodes and fail to achieve symptom remission (Lieber-
man et al., 1996; Robinson et al., 1999b). Through this quences through the induction of sensitization and/or
oxidative stress (Lieberman et al., 1997; Laruelle, 2000).process of repeated exacerbations and relative remis-
sions, most patients sustain the clinical deterioration In contrast, the functional activity of dopamine may be
decreased in the neocortex in schizophrenia (Davis etthat is the hallmark of schizophrenia and that leads to
an end-stage of the illness in which severely affected al., 1991; Okuba et al., 1997; Akil et al., 1999).
Glutamate has also been implicated in schizophreniapatients exhibit persistent symptoms and profound
functional disability (Figure 1). Interestingly, this pattern by studies of behavioral effects of NMDA receptor an-
tagonists (e.g., PCP, MK-801, ketamine) and in the con-of clinical deterioration is most pronounced in the early
stages of the illness (first 5–10 years) and then reaches text of the NMDA receptor hypofunction hypothesis
(Javitt and Zukin, 1991; Olney and Farber, 1995; Jentscha plateau (although the most severe variants may con-
tinue to decline into senescence [Harvey et al., 1999]). and Roth, 1999). Acute administration produces psy-
chotic symptoms and cognitive dysfunction in healthy
subjects (Krystal et al., 1994) and exacerbates psy-Pathogenesis and Pathophysiology
chotic, negative, and cognitive symptoms in patientsA major challenge in schizophrenia research has been
with schizophrenia (Lahti et al., 1995). NMDA receptorto understand how a genetically mediated, neurodevel-
hypofunction induced by the administration of NMDAopmental disorder is not expressed clinically until 1.5–3
antagonists results in decreased corticofugal inhibitiondecades postnatally, but then proceeds to progressively
of subcortical dopamine neurons and consequent in-disable its victims. It is hypothesized that the interaction
creased mesolimbic dopamine release (Breier et al.,of a genetic diathesis and early neurodevelopmental
1998; Kegeles et al., 2000), while chronic administrationinsults result in defective connectivity between a num-
produces decreased release, or hypoactivity, of dopa-ber of brain regions, including the midbrain, nucleus
mine in the prefrontal cortex (Jentsch and Roth, 1999).accumbens, thalamus, temporo-limbic, and prefrontal
It has also been suggested that hypofunctioning NMDAcortices (Selemon and Goldman-Rakic, 1999). This de-
receptors can cause an excess compensatory releasefective neural circuitry is then vulnerable to dysfunc-
of glutamate that can overactivate other glutamate re-tion when unmasked by the developmental processes
ceptor subtypes that are not being antagonized andand events of adolescence (myelination, synaptic prun-
are functionally active (Moghaddam and Adams, 1998;ing, and hormonal effects of puberty on CNS) and expo-
Duncan et al., 2000). Finally, NMDA receptor hypofunc-sure to stressors as the individual moves through the
tion may also produce disturbances in neuroplasticityage of risk (Lieberman et al., 1997; Raedler et al., 2000)
of neurons by altering synaptic connectivity.(Figure 1).
These factors have prompted speculation about
which neurochemical systems might mediate the pro- Structural Pathology
Structural brain abnormalities have also been exten-gressive changes seen during the early phases of
schizophrenia (Lieberman, 1999). Such speculation has sively documented in individuals with schizophrenia
(McCarley et al., 1999). These include enlargement ofcentered on the dopamine and glutamate systems (Fig-
ure 2). An overactivity of dopamine neurotransmission the lateral and third ventricles and reduced volume of
the cortical gray matter and related structures. The latterin the mesencephalic projections to the limbic striatum
has long been suspected in schizophrenia. However, changes do not appear to represent a uniform abnormal-
ity, but rather to effect preferentially certain associationthe evidence supporting the involvement of dopamine
had, until recently, been predominantly indirect. This cortices including those located in the superior temporal
gyrus, the dorsal prefrontal cortex (PFC), and limbicincluded the positive correlation between the clinical
potency and D2 binding affinity of antipsychotic drugs, areas such as the hippocampal formation and anterior
cingulate cortex (Goldstein et al., 1999; McCarley et al.,on one hand, and the ability of indirect dopamine ago-
nists to induce psychosis in healthy volunteers and pro- 1999) (Figure 2). Many of these structural abnormalities
are evident in first-episode, never-medicated subjectsvoke psychotic symptoms at very low doses in patients
Neuron
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Figure 2. Affected Brain Regions in Sci-
zophrenia
Schematic diagram summarizing some of the
brain regions that have most consistently
been implicated in the pathophysiology of
schizophrenia. The nature of the pathophysi-
ological changes appears to differ across re-
gions with a reduction in neuronal number
reported in some nuclei of the thalamus, de-
creases in markers of synaptic connectivity
in the prefrontal cortex and hippocampal for-
mation, and evidence of either a functional
excess or deficit of dopamine neurotransmis-
sion in the striatum and prefrontal cortex, re-
spectively.
with schizophrenia, and may be present prior to the clini- subsequent studies (Harrison, 1999). Reduced hippo-
campal volume also does not appear to be attributablecal onset of illness, suggesting that they reflect the pri-
mary disease process and are not a secondary conse- to decreased neuronal number, but several independent
studies have found reductions in neuronal cell body sizequence of the illness or of its treatment. In addition,
longitudinal neuroimaging studies have shown apparent in various subregions of the hippocampus proper (Benes
et al., 1991; Arnold et al., 1995; Zaidel et al., 1997). Inneuropathological progression in the form of gray matter
volume decreases and fluid compartment increases (in addition, there are consistent reports of reductions in
the gene products for synaptophysin and related pre-lateral and third ventricles and subarachnoid space)
over the course of the illness (Davis et al., 1998; Gur et al., synaptic markers and in dendritic markers, such as mi-
crotubule-associated protein, in certain subdivisions of1998a; Rapoport et al., 1999). The fact that postmortem
studies have not found evidence of gliosis is consistent the hippocampus (see Weinberger, 1999, for review).
Although these findings are limited in a number of re-with an emphasis on the hypothesized role of neurode-
velopmental factors in the pathogenesis and pathophys- spects, they have given rise to testable models postulat-
ing that genes involved in the formation and mainte-iology of schizophrenia (Harrison, 1999). However, re-
cent evidence also suggests the possible involvement nance of hippocampal circuitry play a role in disease
vulnerability (Weinberger, 1999).of apoptotic mechanisms (Jarskog et al., 2000).
In general, the magnitude and consistency of gray
matter reduction in the PFC is not as robust as in theCircuitry-Based Pathological Changes
Understanding the pathophysiological significance of hippocampal formation. However, multiple studies of
the PFC have been motivated by the observation thatthese structural brain abnormalities requires knowledge
of which specific neural elements are affected and how subjects with schizophrenia consistently perform poorly
on certain cognitive tasks, such as those requiring work-the disturbances in different brain regions may be re-
lated. To date, these questions have been most exten- ing memory, that are subserved by circuitry involving the
dorsal PFC (Goldman-Rakic, 1994). In addition, thesesively explored for the neural circuitry of the hippocam-
pal formation and the dorsal PFC. subjects fail to show normal activation of the dorsal
lateral PFC (e.g., Brodmann area 46) when attemptingMultiple imaging and postmortem studies over the
past 2 decades have documented a slight bilateral re- to perform the Wisconsin Card Sort Task, N-back tasks,
or other tasks that require working memory (Weinbergerduction in the volume of the hippocampal formation
(Harrison, 1999; McCarley et al., 1999), an observation et al., 1986; Taylor, 1996). Since the long-term prognosis
for individuals with schizophrenia appears to be bestsupported by more recent in vivo proton spectroscopy
findings of reduced hippocampal N-acetyl aspartate, a predicted, not by the severity of positive symptoms, but
by the degree of cognitive impairment (Green, 1996;putative marker of neuronal pathology, in both unmedi-
cated adult and childhood onset subjects with schizo- Weinberger and Gallhofer, 1997), understanding the na-
ture of PFC brain abnormalities may be particularly im-phrenia (Bertolino et al., 1998). In addition, positron
emission tomography studies have provided evidence portant for improving clinical outcome.
Many, but not all, postmortem studies have reportedof hippocampal dysfunction during episodic memory
retrieval in subjects with schizophrenia (Heckers et al., a 5%–10% reduction in cortical thickness, with a corre-
sponding increase in cell packing density, but no change1998). Initial reports of hippocampal neuron disarray
or misplaced neurons in the superficial layers of the in total neuron number, in the dorsal PFC of subjects
with schizophrenia (Selemon and Goldman-Rakic, 1999).adjacent entorhinal cortex have been widely cited, but
these observations have not been replicated in most Although the size of some PFC neuronal populations,
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particularly pyramidal neurons in deep layer 3, is smaller visual system hold for MD-PFC connectivity, then a simi-
in schizophrenic subjects (Rajkowska et al., 1998), these lar reduction in GAD67 mRNA expression would be ex-
findings are also likely to reflect a decrease in the num- pected in the PFC of subjects with schizophrenia. Con-
ber of axon terminals, distal dendrites, and dendritic sistent with this prediction, GAD67 mRNA and protein
spines that represent the principal components of corti- levels have been reported to be reduced in the PFC of
cal synapses. Consistent with this interpretation, levels subjects with schizophrenia (Akbarian et al., 1995; Costa
of synaptophysin, a presynaptic terminal protein, have et al., 2000; Volk et al., 2000). Furthermore, it appears
been found to be decreased in the PFC of subjects with that a subset of GABA neurons (z25%) is primarily af-
schizophrenia in multiple studies (Perrone-Bizzozero et fected. For example, the density of GABA transporter-
al., 1996; Glantz and Lewis, 1997; Karson et al., 1999; immunoreactive axon cartridges (the distinctive, verti-
Honer et al., 1999). Furthermore, as in the hippocampus, cally arrayed axon terminals of GABAergic chandelier
levels of N-acetyl aspartate, a marker of axonal and/or neurons, which synapse exclusively on the axon initial
neuronal integrity, are reduced in the PFC of subjects segment of pyramidal neurons), is selectively decreased
with schizophrenia (Bertolino et al., 2000). in the dorsal PFC of subjects with schizophrenia (but
The reason for this reduction in synaptic connectivity not in individuals with other psychiatric disorders) with
in the PFC is not fully known. One contributing factor the reduction most evident in the middle cortical layers
may be fewer projections from the thalamus. Indeed, (Pierri et al., 1999).
enlargement of the third ventricle (whose lateral bound- Thus, correlative evidence across a range of observa-
aries are formed by the thalamus) appears to reflect a tions suggests that schizophrenia is associated with
reduction in size of the thalamus (Andreasen et al., 1994; impaired MD-PFC connectivity. Given the dependence
Buchsbaum et al., 1996; Frazier et al., 1996; Gur et al., of working memory tasks on the integrity of this circuitry,
1998b). Moreover, thalamic volume has been correlated it would not be surprising if such an impairment could
with prefrontal white matter volume in subjects with account for working memory dysfunction in schizophre-
schizophrenia, suggesting that a reduction in thalamic nia. The relationship of this impairment to the positive
volume is associated with fewer axonal projections to and negative symptoms of schizophrenia is less obvi-
the PFC (Portas et al., 1998). Consistent with these ob- ous. Nor is it clear that MD-PFC connections are the
servations, several postmortem studies have revealed primary site of pathogenesis. For example, experimental
a 30% reduction in the total number of neurons in both studies in rodents suggest that dysfunction of the PFC
the mediodorsal thalamic nucleus (MD), the principal may appear postpubertally following perinatal lesions
source of thalamic projections to the PFC, and in the of the hippocampus (Weinberger and Lipska, 1995). Fi-
anterior nuclei, which project to the PFC and anterior nally, the apparent deficits in PFC function are also likely
cingulate cortex, but not in at least some other thalamic to reflect disturbances in both intrinsic and cortico-corti-
nuclei (Pakkenberg, 1990; Popken et al., 2000; Young cal connections (Goldman-Rakic and Selemon, 1997;
et al., 2000). However, the small sample sizes and limited Mirnics et al., 2000).
assessment of potential confounds in these studies indi-
cate that additional investigations in this area are re- Treatment of Schizophrenia
quired.
Much remains to be learned about the etiology and
Despite these limitations, the potential importance of
pathophysiology of schizophrenia, but the efficacy of
these findings is strengthened by the convergence of
treatments for this disorder has been clearly demon-other lines of evidence that support the hypothesis that
strated (see Table 1). Although all available treatmentsschizophrenia is associated with abnormalities in tha-
have limitations in their effectiveness and are associatedlamo-prefrontal connectivity (Figure 3). For example, a
with adverse side effects, it is an established fact thatputative marker of MD axon terminals appear to be re-
antipsychotic medications can alleviate the psychoticduced in the PFC of subjects with schizophrenia (Lewis,
symptoms of the disorder and prevent their recurrence2000). In addition, basilar dendritic spines on PFC deep
(Kane, 1996). Moreover, in doing so, antipsychotic druglayer 3 pyramidal neurons, a principal synaptic target
treatment, strategically used, appears to reduce the de-of the excitatory projections from the MD, have been
gree of clinical deterioration that occurs from progres-reported to be decreased by z25% in subjects with
sion of the illness. This has led to the hypothesis thatschizophrenia (Garey et al., 1998; Glantz and Lewis,
the early identification and treatment of schizophrenia2000). In contrast, pyramidal neurons in at least some
(before or soon after symptom onset) may reduce, orother cortical layers or regions of the same subjects, and
even prevent, the cumulative morbidity of the illnessin individuals with major depressive disorder, appear to
(McGlashan, 1996). Although pharmacotherapy pro-lack or to exhibit less marked changes in spine density.
vides the foundation for the treatment of schziophrenia,Since the elimination of presynaptic axon terminals typi-
various psychosocial therapies can be useful adjunctscally leads to resorption of the postsynaptic dendritic
to drug treatment (Kane, 1996).spine, these observations are consistent with a reduced
Until recently, most pharmacological treatments fornumber of afferents from the MD in schizophrenia.
schizophrenia were based on synaptic modulation ofIn the primate visual system, monocular deprivation,
dopamine neuronal systems mainly by antagonism ofwhich leads to reduced cortical inputs from the thala-
postsynaptic D2 receptors. With the advent of the so-mus, has been associated with a decline in markers of
called atypical antipsychotic drugs, this focus has nowactivity in cortical g-aminobutyric acid (GABA) neurons
broadened to include other neurotransmitters such as(Hendry and Jones, 1988), including the expression of
serotonin, norepinephrine, acetylcholine, histamine, andthe mRNA for glutamic acid decarboxylase (GAD67), the
synthesizing enzyme for GABA. If these findings in the glutamate, as well as various neuropeptides and neu-
Neuron
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Figure 3. Cortical Circuitry in Schizophrenia
Schematic diagram summarizing distur-
bances in the connectivity between the medi-
odorsal (MD) thalamic nucleus and the dorsal
prefrontal cortex (PFC) in schizophrenia.
Postmortem studies have reported that sub-
jects with schizophrenia have (1) decreased
number of neurons in the mediodorsal thala-
mic nucleus; (2) diminished density of parval-
bumin-positive varicosities, a putative marker
of thalamic axon terminals, selectively in
deep layers 3–4, the termination zone of MD
projections to the PFC; (3) preferential reduc-
tion in spine density on the basilar dendrites
of deep layer 3 pyramidal neurons, a principal
synaptic target of the excitatory projections
from the MD; (4) reduced expression of the
mRNA for glutamic acid decarboxylase
(GAD67), the synthesizing enzyme for GABA, in
a subset of PFC GABA neurons; (5) decreased
density of GABA transporter (GAT-1)-immu-
noreactive axon cartridges, the distinctive,
vertically arrayed axon terminals of GABAer-
gic chandelier neurons, which synapse exclu-
sively on the axon initial segment of pyramidal
neurons; and (6) decreased dopamine in-
nervation of layer 6, the principal location of
pyramidal neurons that provide corticotha-
lamic feedback projections (see Lewis, 2000,
for additional details and references).
rosteroids (Kinon and Lieberman, 1996). These com- other neuroreceptors (e.g., 5-HT, noradrenergic, etc.
[Duncan et al., 2000]) in modifying glutamate mediatedpounds have either low ratios of affinities for the D2
and 5-HT2a receptors (called D2/5-HT2 antagonists [e.g., function and behavior.
Schizophrenia researchers have historically usedrisperidone]) or possess affinities for some combination
of multiple neuroreceptors and reuptake sites including pharmacology in a bootstrap approach to simultane-
ously develop treatments and pathophysiological dis-D1,2,3,4, 5-HT1a,b, 2a,c, 3, 6, 7, NEa1, 2, MACH1, 4, H1,2, DAT, NET,
ST (called multi-neuroreceptor antagonists [e.g., cloza- ease models (as previously described). This productive
process of cross-fertilization continues as we see exper-pine]). At present, all effective treatments appear to pos-
sess some threshold level of D2 receptor antagonism, imental treatments and drug development strategies de-
rive from the results of the emerging neuroscience ofthough selective nondopamine antagonists have at-
tempted to challenge this concept (Kapur et al., 2000). schizophrenia (Miyamoto et al., 2001).
At the same time, there is clearly no pharmacologic
“magic bullet” for the different pathologic dimensions Future Directions
These research findings provide new opportunities andof schizophrenia. This is reflected by the common prac-
tice of using multiple drugs in combination when treating new challenges to understanding and treating schizo-
phrenia. Certainly, a major challenge is to determine thepatients with schizophrenia. Whereas, the psychotic
symptoms appear to be mediated primarily by dopamine genetic susceptibilities and pathogenetic mechanisms
that can produce the complex clinical phenotype ofoveractivity in mesolimbic circuits and negative symp-
toms by dopamine underactivity in prefrontal cortical schizophrenia. The identification of pathways of dys-
function, such as thalamo-prefrontal circuitry or the con-neurons (thus can be exacerbated by classical antipsy-
chotics with high D2 affinity), the cognitive impairment nections linking other cortical, subcortical, and cerebel-
lar regions implicated in schizophrenia, permits studiesappears to also involve disturbances in glutamate activ-
ity. Interestingly, the second generation or atypical anti- of the relationships among the various alterations in a
circuit and the elucidation of a putative endophenotype.psychotic drugs, which are thought to have a broader
range of therapeutic effects including reducing cognitive For example, does a given abnormality represent a pri-
mary brain disturbance due to a causal factor of theimpairment, have been found to block the cellular and
behavioral effects of NMDA antagonists, despite the disorder, or does it reflect a downstream pathologic
consequence of the primary brain disturbance or anfact that they lack affinities for any of the ionotropic or
metabotropic glutamate receptors (Mohn et al., 1999; adaptive response that attempts to normalize the func-
tion of the circuit?Duncan et al., 2000). It is therefore assumed that atypical
antipsychotic drugs must be acting more directly through Answers to these types of questions may create new
opportunities for research at the intersection betweendopamine receptors (S. Miyamoto et al., submitted) or
Review
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Table 1. Treatment of Schizophrenia
Interventions Advantages Disadvantages
Pharmacological
Antipsychotic Drugs (APDS)
CLASSICAL: Reduces and prevents recurrence of Limited efficacy against negative and
High-affinity D2 antagonists psychotic symptoms. cognitive symptoms. High rates of
extrapyramidal symptoms (EPS)
and tardive dyskinesia (TD).
ATYPICAL:
Mixed neuroreceptor antagonists; Reduces and prevents psychotic symptoms; Various side effects including blood
low-affinity D2 high affinity 5HT2A broader efficacy against negative mood dyscrasias, weight gain, increased
(e.g., clozapine, risperidone, and cognitive symptoms; may prevent glucose, and triglycerides; more
olanzapine, quetiapine, illness progression. Less EPS and TD. expensive.
ziprasidone)
Adjunctive Treatements of APDS
Benzodiazepines Control agitation. Limited potency and duration of
action.
Mood stabilizers Augment antipsychotic effects; control mood Few studies; limited efficacy.
Anticonvulsants symptoms and hostility.
Lithium
Antidepressants Reduce depressive and negative symptoms. Limited efficacy against negative
symptoms.
Anticholinergics Reduce EPS. Side effects (dry mouth, constipation,
memory impairment).
Dopamine agonists Reduce negative symptoms. Possible exacerbation of psychotic
symptoms.
Experimental Treatments
Dopamine partial agonists (e.g., May reduce psychotic and negative Few clinically available compounds;
aripripazole) symptoms; few side effects. few studies.
5-HT agents (e.g., M100907, May improve negative symptoms; few side No proof of concept as monothera-
ritanserin) effects. peutic agent. Weak effect as
adjunct; few clinically available
compounds.
Cholinergic agonists ? No proof of concept.
(muscarinic/nicotinic)
Glutamatergic agents
Allosteric modulators (e.g., gly- Reduce negative symptoms; may improve Weak to moderate effect; few studies
cine, serine, D-cycloserine) cognition, prevent illness progression. and clinically available com-
pounds.
Glycine uptake inhibitors ? No proof of concept.
Glutamate release-inhibiting ? No proof of concept.
drugs (e.g., LY-293558)
AMPA/kainate receptor ago- May improve congnition. Very few studies.
nists (e.g., CX516)
Protein kinase C inhibitors (e.g., ? No proof of concept.
tamoxifen)
Steroidal agents (e.g., estrogen, May reduce negative symptoms; improve Few studies.
dihydroepiandrosterone) cognition; prevent illness progression.
Phsopholipid compounds (e.g., May improve cognition; prevent illness No proof of concept.
3-omega fatty progression.
Psychosocial
Psychoeducation Increases awareness and insight of patient Few studies; must be combined with
family. drug Rx.
Psychotherapies May be useful adjunct. Limited to problem-oriented and
supportive therapies; must be
combined with drug Rx.
Assertive community treatment Improves Rx compliance. Underutilized more labor intensive.
Cognitive behavioral therapy May reduce positive symptoms. Few studies; must be combined with
drug Rx.
systems level investigations and genetic approaches. niques), and comparison of the chromosomal locations
of these genes with regions implicated in schizophreniaCurrent views hold that schizophrenia is probably a con-
sequence of multiple interacting genes; individually, through linkage studies (Pulver, 2000), may provide con-
vergent approaches to the identification of specific vul-these genes may have relatively little independent influ-
ence, and they may not all be involved in every individual nerability genes. For example, a recent study of gene
expression profiling in the dorsal PFC of subjects withwho meets diagnostic criteria for the illness. Thus, as-
sessment of the patterns of altered gene expression in schizophrenia revealed that, of over 250 gene groups,
the group of genes encoding proteins involved in thethe affected brain circuits of subjects with schizophrenia
(using cDNA microarray technology or related tech- regulation of presynaptic function were most consis-
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tivation of the working memory cortical network in schizophrenia.tently altered (Mirnics et al., 2000). Although the subjects
Am. J. Psychiatry 157, 26–33.with schizophrenia appeared to share a common ab-
Breier, A., Su, T.P., Saunders, R., Carson, R.E., Kolachana, B.A., denormality in the control of synaptic transmission, the
Bartolomeis, A., Weinberger, D.R., Weisenfeld, N., Malhotra, A.K.,specific combinations of genes involved in presynaptic
Eckelman, W.C., and Pickar, D. (1997). Schizophrenia is associated
function that showed reduced expression differed among with elevated amphetamine-induced synaptic dopamine concentra-
them. Interestingly, a number of the chromosomal loci tions: evidence from a novel positron emission tomography method.
that have been implicated in schizophrenia contain Proc. Natl. Acad. Sci. USA 94, 2569–2574.
genes encoding proteins related to presynaptic function Breier, A., Adler, C.M., Weisenfeld, N., Su, T.P., Elman, I., Picken,
(Mirnics et al., 2000). L., Malhotra, A.K., and Pickar, D. (1998). Effects of NMDA antago-
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of a novel PET approach. Synapse 29, 142–147.phenotype of schizophrenia may be the result of multiple
Bromet, E.J., and Fennig, S. (1999). Epidemiology and natural historypathophysiological processes occurring at different
of schizophrenia. Biol. Psychiatry 46, 871–881.stages of the illness (Lieberman, 1999). These can be
Brzustowicz, L.M., Hodgkinson, K.A., Chow, E.W.C., Honer, W.G.,further characterized using multiple investigative ap-
and Bassett, A.S. (2000). Location of a major vulnerability locusproaches including in vivo neuroimaging, genetics, mo-
for familial schizophrenia on chromosome 1q21-q22. Science 288,
lecular neuropathology, and the development of animal 678–682.
models. Although animal models can only approximate Buchsbaum, M.S., Someya, T., Teng, C.Y., Abel, L., Chin, S., Najafi,
the complex clinical phenotype of schizophrenia, they A., Haier, R.J., Wu, J., and Bunney, W.E., Jr. (1996). PET and MRI
are essential to understand the molecular and cellular of the thalamus in never-medicated patients with schizophrenia.
Am. J. Psychiatry 153, 191–199.mechanisms that underlie the pathogenesis and patho-
physiology of schizophrenia and can be used to test Carlsson, A. (1988). The current status of the dopamine hypothesis
of schizophrenia. Neuropsychopharmacology 1, 179–186.predictions from direct investigations of the illness. For
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